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Abstract: Glaucoma is one of the most common neuropathies of the optic nerve. An elevated 
intraocular pressure (IOP) is a well documented risk factor for the development and progression 
of this disease. Until now, IOP reduction is the only well documented successful method of 
glaucoma treatment. Among the many hypotensive drugs, prostaglandin analogs are proved to 
be the most potent antiglaucoma agents, with very few systemic side effects. A new prostanoid 
FP receptor analog, tafluprost, has been introduced into the medical treatment of glaucoma 
and ocular hypertension. Many studies have shown that it is an efficient IOP-lowering drug, 
and that it is safe and well tolerated. A preservative-free tafluprost formulation is as potent as 
a preserved one, but it has fewer and milder toxic effects on the eye.
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Introduction
Glaucoma is one of the most common neuropathies of the optic nerve. It causes 
progressive atrophy of the optic disc resulting in typical defects in the visual field.1 
It can lead to total loss of vision if left untreated.2,3 Indeed glaucoma is the second 
most common cause of blindness worldwide.3,4 Unfortunately, the pathogenesis of 
this disorder is not fully explained. Because elevated intraocular pressure (IOP) is 
known to be the main risk factor for development and progression of glaucoma, its 
therapy relies nowadays on IOP reduction.5–10 Topical use of antiglaucoma drugs is 
probably the most commonly used tool for this. Among the many topical hypotensive 
medications, prostaglandin analogs are proved to be the most potent in lowering IOP 
and with very few systemic side effects.11,12 For these reasons, they are recommended 
as first-line therapy for this disease.3,11,13,14
Prostaglandin analogs were first proposed for glaucoma treatment by Camras and 
Brito.14–16 Nowadays, derivatives of prostaglandin F2α, ie, latanoprost, travoprost, 
unoprostone, and a prostamide, bimatoprost, are commercially available. In van der 
Valk’s meta-analysis, latanoprost reduced IOP by 28%–31% from baseline, travoprost 
by 29%–31%, and bimatoprost by 28%–33%.12 Latanoprost and travoprost are selective 
prostanoid FP receptor agonists, and by binding to these receptors they exert their IOP-
lowering effect.17–21 Bimatoprost is a prostamide, the exact molecular mode of action of 
which is not clearly understood.14,18,21 All these compounds decrease IOP by increasing 
aqueous outflow, mainly through the uveoscleral (unconventional) route.14,22 In young 
individuals, up to 30% of aqueous fluid flows out through the unconventional route, but 
this drops during aging.22 Hypotensive lipids can increase aqueous fluid outflow by up Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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to 50%.22 Moreover, they do not have an effect on aqueous 
production.14 They probably act by increasing the activity of 
matrix metalloproteinases and widening the spaces between 
ciliary muscle bundles.14 It has been found that the increase 
in uveoscleral outflow may also be due to relaxation of the 
ciliary muscle, leading to widening spaces between muscle 
bundles.14 Ester forms of PGF2α derivatives penetrate the 
cornea much better. This is why all prostanoids except for 
bimatoprost are administered topically as prodrugs. After 
entering the cornea, they are hydrolyzed by corneal esterases 
to their active carboxylic acid forms.17
Preclinical and animal studies
Prostaglandin derivatives have a strong, long-lasting, stable 
IOP-lowering effect with few systemic side effects.4,14,17 
Unfortunately, they may induce local adverse side effects, 
including conjunctival and ocular hyperemia, iris and 
periocular skin pigmentation, and eyelash growth.4,17,23 
There have been efforts to find other prostanoid FD receptor 
agonists which are more potent in reducing IOP but with 
fewer and milder side effects.17,21,24 In preclinical in vitro 
and in vivo studies, Nakajama et al tested different PGF2α 
derivatives and found that 15,15 difluoro PGF2α derivatives 
retained iris constrictor activity, decreased IOP in conscious 
monkeys, but did not increase the melanin content of 
cultured B16-F10 melanoma cells.17 This last observation 
was confirmed by Tagaki et al, who also demonstrated an 
ocular hypotensive effect for this compound. This effect 
was present in normotensive monkeys and in laser-induced 
ocular hypertension. The effect was dose-dependent, with 
a peak at eight hours after administration.24 Moreover, the 
effect was stronger and more continuous than that induced 
by latanoprost.24 Reduction of IOP was dose-dependent in 
the eyes of ddY mice.19 This effect was similar to the effect 
of travoprost, but stronger and more longer-lasting than 
after administration of latanoprost.19 In this animal model, 
Ota et al also found that tafluprost lowered IOP via prostanoid 
FP receptors, and that part of the hypotensive effect may be 
related to FP receptor-mediated prostaglandin production and 
stimulation of EP3 receptors.20 This IOP-lowering effect in 
mice was confirmed by Akaishi et al.25
It has been postulated that alterations in optic nerve 
head blood flow may be involved in the pathogenesis of 
glaucoma.1,26 For this reason, improvement in ocular blood 
flow by glaucoma therapy may be helpful. Studies assess-
ing the influence of the available prostaglandin analogs 
on ocular blood flow have yielded both positive and nega-
tive results.14 In a study by Izumi et al tafluprost 0.0015% 
significantly increased retinal blood flow and blood velocity 
as measured by laser Doppler velocimetry in cats.29 This 
observation was then confirmed by Akaishi et al27 who 
found that optic nerve head blood flow increased in rabbit 
eyes after 28 days’ administration of any of the three F2α 
prostaglandin analogs, ie, tafluprost, latanoprost, or tra-
voprost. Moreover, the increase induced by tafluprost was 
greater than that induced by latanoprost or travoprost.27 
Tafluprost also increased optic nerve head blood flow 
in both normal and experimental glaucomatous eyes in 
monkeys.28 Dong et al wanted to determine if tafluprost 
could relax precontracted rabbit ciliary arteries, and found 
that it induced concentration-dependent relaxation but by 
a mechanism that was independent of endothelial-derived 
factor.26 In the future, these findings are likely to be shown 
to be real additional effects of antiglaucoma drugs. At this 
time we do not possess reliable tools for blood flow mea-
surement, and thus the beneficial role of improvement in 
ocular blood flow cannot as yet be ascertained.29,30
Another interesting question concerning antiglaucoma 
agents concerns their neuroprotective properties. A direct 
antiapoptotic effect in cultured retinal ganglion cells (RGC-
5s) and rat retinal ganglion cells with optic nerve crush was 
identified by Kanamori et al. In an in vitro model, tafluprost 
promoted cell viability in a dose-dependent manner, sig-
nificantly reducing the number of caspase 3-positive cells 
and suppressing [Ca2+] evoked by exogenous glutamate. In 
an in vivo rat model, tafluprost increased the survival rate 
of ganglion cells in eyes treated with this drug for 14 days 
after optic nerve crush.31 These observations suggest that 
tafluprost possesses an antiapoptotic effect in retinal ganglion 
cells in rats.
Pharmacology, pharmacokinetics, 
and clinical efficacy
Tafluprost (1-methylethyl (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-
3,3-difluoro-4-phenoxy-1-butenyl]-3,5-dihydroxycyclo-
pentyl]-5- heptenoate)24,31 is a 16-phenoxy analog of PGF2α, 
with a 15,15-difluoro substitution.21 It is presently available 
in two formulations, ie, with benzalkonium chloride (BAK)-
Tapros® in Japan (Santen Pharmaceutical Co. Ltd., Osaka, 
Japan) and preservative-free in Europe, ie, Taflotan® (Santen 
Oy, Finland), both in 0.0015% (15 µg/mL) concentrations.21 
Tafluprost differs from the other prostanoids available on 
the market because it possesses two fluorine atoms at the 
carbon 15 position, instead of the hydroxyl group present in 
latanoprost, travoprost, and bimatiprost.14,22 It is an isopropyl 
ester (AFP-168) and, like other prostaglandin analogs, is Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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rapidly hydrolyzed by corneal esterases to the free acid of 
tafluprost (AFP-172), which is its active form.14,21,24 AFP-
172 is a very potent FP receptor agonist, with a Ki of 0.4b 
nM.17,24 Its affinity for the human prostanoid FP receptor is 
12 times that of the carboxylic acid in latanoprost and 1700 
times that in unoprostone. It also has a 126-fold higher affin-
ity for FP receptors than for EP3 receptors, and negligible 
affinity to other prostanoid receptors (DP, EP2, IP, TP).24 
Tafluprost increases in vivo uveoscleral outflow as mea-
sured by fluorophotometry.24 After either single or repeated 
topical dosing, the plasma concentration of tafluprost is low. 
Moreover, it is cleared rapidly from the circulatory system. 
Its active form, ie, tafluprost acid, can be detected in plasma 
for up to one hour after topical administration, with a peak 
at 10 minutes.3 It is thought that the pharmacologic profile 
of this compound is similar to that of other prostaglandins 
available on the market.32
The pharmacodynamics, safety, and tolerability of 
tafluprost in healthy volunteers were assessed in a clinical, 
masked, placebo-controlled Phase I study.23 Tafluprost 
0.0025% and 0.005%, latanoprost 0.005%, and placebo 
were given for seven days. The decline in IOP from base-
line was 4.3 mmHg for tafluprost 0.0025%, 6.8 mmHg 
for tafluprost 0.005%, 5.3 mmHg for latanoprost, and 
3.1 mmHg for placebo. The decrease in IOP values ver-
sus baseline was significant for all treatment groups, and 
superior with tafluprost 0.005% to values with placebo and 
latanoprost 0.005%. In another placebo-controlled Phase I 
study, healthy volunteers were given sequential ascending 
doses of tafluprost, ie, 0.0001%, 0.0005%, 0.0025%, and 
0.005%.4 For all these doses, a decreasing IOP effect was 
present as compared with placebo. The effect was dose-
dependent and significant for concentrations of 0.0005%, 
0.0025%, and 0.005%. The effect was maximal at 12 hours 
after administration and lasted throughout the duration of 
treatment.4 The therapeutic concentration of tafluprost was 
set at 0.0015% as a result of a Phase II dose-response study 
performed in Japan.21 In a randomized, double-masked, 
controlled, multicenter, multinational Phase II study, 
Traverso et al assessed the duration and stability of the 
IOP-lowering effect and tolerability of tafluprost 0.0015% 
compared with latanoprost 0.005% in patients with primary 
open-angle glaucoma, exfoliation glaucoma, or ocular 
hypertension.33 They observed that maximum reduction of 
IOP was reached by day 7 of treatment and sustained until 
day 42. They showed that tafluprost 0.0015% decreased IOP 
from baseline by 9.7 ± 3.3 mmHg and latanoprost 0.005% 
by 8.8 ± 4.3 mmHg.33
Phase III clinical studies were conducted in Japan and in 
Europe. In the first one, the efficacy of tafluprost with that 
of latanoprost in 109 patients with open-angle glaucoma 
and ocular hypertension were compared.21 After four weeks 
of administration, they observed reduction in IOP by 
6.6 ± 2.5 mmHg (27.6 ± 9.6%) in the tafluprost group and 
by 6.2 ± 2.5 mmHg (25.9 ± 9.7%) in the latanoprost group.21 
A second Phase III study involving 351 Japanese patients with 
open-angle glaucoma or ocular hypertension showed that the 
reduction in IOP from baseline was stable throughout 52 weeks 
and varied from 4.9 to 5.7 mmHg.21 A potent effect of taflu-
prost 0.0015% on IOP and the safety of this medication were 
also demonstrated in a randomized, parallel-group, double-
masked European Phase III study conducted in 49 centers 
in eight countries for up to 24 months.34 The objective of 
this study was to compare the efficacy and safety profiles of 
tafluprost 0.0015% and latanoprost 0.005% in 533 patients 
with open-angle glaucoma and ocular hypertension. Patients 
had not only primary open-angle glaucoma but also pigmen-
tary and exfoliative disease. Both drugs exerted a potent and 
significant IOP-lowering effect throughout the study, with 
average decreases of 6–8 mmHg (27%–31%) for tafluprost 
and 7–9 mmHg (29%–35%) for latanoprost. These results are 
in line with those of other prostaglandins, as shown in the van 
der Valk meta-analysis.12 After 24 months, the mean decrease 
in IOP from baseline was 7.1 mmHg (29.1%) in the group 
treated with tafluprost and 7.7 mmHg (32.2%) in the group 
treated with latanoprost.34
The primary aim of the randomized, investigator-masked, 
multicenter, crossover Phase III study described by 
Hamacher et al was to evaluate the pharmacodynamics 
and safety of preserved and preservative-free tafluprost 
0.0015% in patients with open-angle glaucoma or ocular 
hypertension. These investigators observed similar 
reductions in IOP of .5 mmHg with preservative-free and 
preserved formulations.11 A preservative-free tafluprost 
0.0015% formulation also lowered IOP effectively in a 
population with poor IOP control with prior medications. 
Mean IOP reduction in 544 screened patients was from 
19.4 ± 5.0 mmHg at baseline to 15.3 ± 3.5 mmHg after 
12 weeks of tafluprost treatment. In total, 79.5% of eyes 
treated with the preservative-free formulation of tafluprost 
achieved IOP # 18 mmHg 12 weeks after switching 
medication.35 Other Phase III studies indicated that 
tafluprost, like other prostaglandin analogs, may also exert an 
additional IOP-lowering effect when administered together 
with the β-blocker, timolol, in cases when monotherapy is 
not adequate.36Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Safety and tolerability
In 2007, Sutton et al observed in a Phase I clinical study 
that systemic safety was similar for tafluprost, latanoprost, 
and placebo when administered to eyes. Investigators did 
not observe clinically significant changes in laboratory 
parameters, vital signs, or electrocardiographic parameters 
in any of 49 participants throughout the course of the study. 
Visual acuity and funduscopic pictures of tested eyes were 
also stable. Aqueous flare, measured by a laser flare cell 
meter, decreased over time. Ocular adverse effects were 
only mild to moderate in severity. The most common side 
effect was ocular hyperemia. This was more frequent after 
administration of tafluprost in concentrations of 0.0025% or 
0.005% than after administration of latanoprost 0.005%.23 
The incidence of photophobia was greater in the tafluprost 
group than in the latanoprost group. It is noteworthy that the 
doses used in this study exceeded the dose in the currently 
available preparations, ie, 0.0015%. Similar observations 
were made in another Phase I study.4 Tafluprost was well 
tolerated. The most frequently observed adverse effect was 
mild, concentration-dependent hyperemia.4 Mild chemosis 
was also observed in two of 16 patients receiving tafluprost 
0.0001%. Interestingly, the authors stated that rates of adverse 
effects were similar for the tafluprost 0.0001% and 0.0025% 
and latanoprost 0.005% groups, but rates of ocular hyperemia 
was significantly lower in eyes receiving latanoprost.4 These 
authors did not find either cells or flare in the anterior chamber 
or abnormalities of the iris, lens, or vitreous humor in any 
eyes during the study.4 All adverse events described in the two 
aforementioned studies were mild to moderate and did not 
result in treatment discontinuation.4,23 Similar observations 
were made by Uusitalo et al who administered preserved and 
preservative-free formulations of tafluprost. No serious side 
effects or withdrawals occurred during their study. Ocular 
adverse events were of mild or moderate severity, with the 
most prevalent being ocular hyperemia.3
A Phase III study described by Uusitalo analyzed the 
safety of tafluprost 0.0015% versus latanoprost 0.005% over 
24 months in a representative group of 533 patients.34 Both 
drugs were well tolerated. Reported adverse events were only 
mild to moderate. The authors found that during the 24 month 
study period, at least one adverse event was reported by 176 
of 264 (66.7%) of patients receiving tafluprost, and by 162 
of 264 (61.4%) of patients receiving latanoprost. Nonocular 
adverse events were reported by 133 (50.4%) patients treated 
with tafluprost, and by 114 (43.2%) with latanoprost, but only 
11 in the tafluprost group and nine in the latanoprost group, 
respectively, were considered to be related to treatment.34 The 
authors did not find any clinically significant changes in blood 
pressure or heart rate during the 24 month study period, or in 
laboratory parameters up to 12 months. LogMAR scale scores 
for best corrected visual acuity remained stable throughout 
the study. Ocular adverse effects were reported by 48.1% of 
patients in the tafluprost group and by 44.3% patients in the 
latanoprost group. Most frequently reported were conjunc-
tival hyperemia and ocular redness. The stimulating effect 
on eyelash growth was absent or mild in .90% of patients 
after month 24 in both the tafluprost and latanoprost groups. 
A slight overall tendency towards corneal thinning was 
observed in both groups of patients during the study, but the 
changes were comparable between the groups.34
It is known that PGF2α derivatives cause an increase in 
iris and periocular skin pigmentation.17,21 This was observed 
in 43%–56% of patients receiving latanoprost for longer 
than one year.37 Moreover, the pigmentation increases with 
prolonged therapy.23,37 Latanoprost was reported to increase 
melanogenesis in cultured melanoma cells. The carboxylic 
acid in latanoprost increased the melanin content of cultured 
B16–B10 melanoma cells in a dose-dependent manner, but 
derivatives possessing two fluorine atoms at the 15-position 
as AFP-172 (carboxylic acid of tafluprost) did not, even at 
the maximal dose.17 The same results were obtained in 2004 
by Tagaki et al.24 Such observations led to the suggestion that 
tafluprost may induce a lower incidence of iris and periocular 
skin pigmentation than latanoprost.24 In a long-term Phase III 
study, Uusitalo et al reported slightly more cases of iris pig-
mentation in the group treated with latanoprost (28%) than 
in those treated with tafluprost (26.1%), but these differences 
were not significant.34
Toxic adverse effects
Toxic adverse reactions to antiglaucoma topical medica-
tion may be only minimal or be very severe. The cytotoxic 
effects of these drugs cause damage and death of conjunc-
tival and corneal epithelial cells. This can lead to epithe-
liopathy of the cornea and conjunctiva. Inflammation may 
be the first sign of a toxic drug effect on superficial tissues 
of the eye. This is caused by activation of the inflamma-
tory response in the conjunctiva, either acute or chronic. 
This could be papillary, with generalized injection, or 
follicular, caused by proliferation of lymphocytes and plasma 
cells.38 Unfortunately, such inflammatory changes create 
a potential risk for failure of further glaucoma filtration 
surgery.39,40 These changes may also lead to keratinization 
and conjunctival scarring, with symblepharon formation,   
known as drug-induced pseudopemphigoid.3,11,38 Many of Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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these undesirable effects are connected with the preservatives 
present in eye drop formulations.2 The adverse influence of 
preservative-containing topical antiglaucoma medications 
on cells and tissues on the eye surface is well documented 
in in vitro and in vivo studies.2,32,38,41 BAK is the most 
commonly used preservative in eye drops.42 It has already 
been found that this compound exerts cytotoxic (proapoptotic 
and pronecrotic) effects on the ocular surface and trabecular 
meshwork cells.43–45 It also causes reduction of cellular 
viability, infiltration of conjunctival stroma, and overexpres-
sion of inflammation- or apoptosis-related molecules, such as 
Apo-2,7, Fas (CD45), HLA-DR, ICAM-1.32,38,46–52 Moreover, 
decreased expression of MUC5AC on the conjunctival cells 
were found in impression cytology specimens taken from 
patients treated locally with antiglaucoma drugs containing 
BAK. This phenomenon may explain the high prevalence of 
dry eye syndrome in patients after prolonged antiglaucoma 
therapy.34,50,53
Solutions which are preservative-free, have lower BAK 
concentrations, or contain alternative preservatives were 
introduced into topical glaucoma therapy to minimize side 
effects.2 Among the widely used prostaglandin analogs, 
only tafluprost is available in a BAK-free formulation.3,42 
A preservative-free solution of tafluprost showed reduced 
toxicity in human conjunctival epithelial cell lines when 
compared with preserved latanoprost, travoprost, and 
bimatoprost.54 Tafluprost had low proapoptotic/pro-oxidative 
effects in vitro when compared with preservative-containing 
formulations.54 Liang et al assessed conjunctival and cor-
neal reactions to preservative-free tafluprost, commercially 
available latanoprost, and benzalkonium chloride 0.02% in 
in vivo studies.45 Corneal epithelium confocal microscopy 
in vivo revealed partial desquamation of epithelial cells, 
irregular cell shapes, anisocytosis and loss of cell borders, 
abnormal reflectivity patterns, swollen cells, and inflammatory 
infiltrations in rabbit eyes treated with latanoprost and BAK 
solution. Rabbit corneas treated with preservative-free 
tafluprost were almost normal, with the epithelium having 
a regular polygonal mosaic appearance, brightly reflective 
nuclei, and no obvious desquamation or swelling. A slight 
inflammatory infiltrate in the anterior corneal stroma was 
observed only after administration of BAK. Inflammatory 
infiltrations in the peripheral cornea and the limbus area 
were noted after exposure to latanoprost or BAK, but not 
after exposure to preservative-free tafluprost.45 Similarly, con-
junctival stroma vessels showed rolling of inflammatory cells 
after installation of BAK or latanoprost. After installation 
of preservative-free tafluprost, normal blood vessels were 
observed, without any rolling of inflammatory cells. 
Moreover, significant inflammatory infiltration in specimens 
taken from eyes exposed to latanoprost and abundant inflam-
matory cell patches in those exposed to BAK were observed 
in conjunctival impression cytology specimens.45 Specimens 
taken from eyes exposed to latanoprost and BAK showed 
a higher expression of CD45+ cells than those exposed to 
tafluprost without preservative. Similarly, expression of 
tumor necrosis factor receptor 1 in conjunctival impression 
cytology samples was highest in patients treated with BAK 
or latanoprost. Only a few TUNEL+ cells were observed 
after installation of preservative-free tafluprost but more of 
these cells were present after installation of latanoprost or 
BAK.45 These observations established the lower toxicity of 
the preservative-free formulation to the anterior segment of 
the eye.45
BAK is thought to be an ocular penetration enhancer 
for topically administered drugs, because it increases the 
corneal permeability of pharmacologic agents.42,55 Pellinen 
and Lokkila evaluated corneal penetration of preserved and 
preservative-free tafluprost 0.0015% into rabbit aqueous 
humor after topical application. They noticed that there 
were no significant between-group differences in mean 
concentrations of tafluprost acid in the aqueous humor. 
They concluded that BAK at the concentration used in the 
tafluprost formulations did not affect corneal penetration 
of this drug into rabbit aqueous humor.55 It is possible that 
tafluprost has its own high corneal penetrating ability and 
BAK would not enhance it.55 In a Phase I study evaluat-
ing the pharmacokinetics and efficacy of preserved and 
preservative-free tafluprost, Uusitalo et al did not observe 
any significant differences in pharmacokinetic parameters 
between the formulations, after either single or repeated 
dosing.3 Ocular hyperemia occurred with the same frequency 
in both groups, but was predominantly of moderate severity 
in eyes treated with preserved tafluprost, and of mild severity 
in those treated with the preservative-free formulation.3 The 
safety of preserved and preservative-free tafluprost was also 
assessed in a Phase III study.11 In contrast with the findings 
of Uusitalo et al it was shown that conjunctival hyperemia 
was reported more often by people using preservative-
free tafluprost.11 The aforementioned studies showed that 
IOP reduction obtained by preservative-free tafluprost is 
equivalent to that achieved by the preserved formulation. 
It seems that removing the preservative BAK from the 
tafluprost formulation does not change the IOP-lowering 
properties of preparation.11,42 Because the aim of designing 
a preservative-free prostaglandin formulation was to reduce Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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toxic effects and clinical complications in patients treated 
for glaucoma and ocular hypertension, it was reasonable to 
check if preservative-free tafluprost was a genuine alterna-
tive for patients receiving prostaglandins other than taflu-
prost. Uusitalo et al investigated the hypotensive effect and 
tolerability of preservative-free tafluprost in patients with 
open-angle glaucoma and ocular hypertension exhibiting 
ocular surface side effects during latanoprost treatment.32 
Twelve weeks after switching from preserved latanoprost 
to preservative-free tafluprost, IOP was maintained at the 
same level. IOP values were 16.8 ± 2.5 mmHg at baseline 
and 16.4 ± 2.7 mmHg at weeks 2, 6, and 12 of tafluprost 
treatment.32 The number of patients with ocular side effects, 
ie, conjunctival hyperemia, and corneal and conjunctival 
fluorescein staining, was reduced by 50% after switching the 
drugs. The same was reported for other ocular symptoms, 
including itching, tearing, irritation, burning, stinging and 
foreign body sensation. After 12 weeks of tafluprost preser-
vative-free treatment, fluorescein break-up time increased 
from 4.5 ± 2.5 seconds at baseline to 7.8 ± 4.9 seconds 
(P , 0.001).32 Results of immunocytologic testing of impres-
sion cytology samples revealed that, after 12 weeks of treat-
ment with preservative-free tafluprost in patients previously 
using latanoprost, there was a significant reduction in those 
expressing abnormal levels (,7%) of MUC5AC-positive 
goblet cells and abnormal levels (.40%) of HLA-DR-
positive epithelial cells.32 This observations may indicate 
a less harmful influence of preservative-free tafluprost on 
the conjunctiva than preserved latanoprost.32 Surprisingly, 
change in Schirmer’s test scores was smaller and statistically 
significant only at week 6 of treatment with the preservative-
free tafluprost formulation.32
Patient compliance and comfort
Tafluprost and preservative-free tafluprost formulations 
were introduced onto the market in 2008. This is probably 
the reason for the relative lack of data on patient satisfaction 
and compliance. In the Uusitalo study, the Comparison 
of Ophthalmic Medications or Tolerability questionnaire 
devised by Barbel et al was used to assess drop discomfort 
in patients treated with preserved latanoprost and switched 
to preservative-free tafluprost.32,56 As the authors described, 
among patients receiving the commercially available 
latanoprost formulation, 30% experienced no negative effect 
on quality of life, 59% experienced “a little or some”, 10% 
“quite a bit or very much”, and 1% “extremely negative”.32 
After switching to preservative-free tafluprost, no negative 
effect on quality of life was reported by 52% of enrolled 
patients, 46% reported “a little or some”, 2% “quite a bit” and 
0% “very much or extremely” after 12 weeks of this therapy. 
The percentage of latanoprost patients who were totally 
satisfied with therapy at baseline was 16%, and 36% were 
very satisfied. At week 12 of treatment with preservative-free 
tafluprost, 32% of patients were totally satisfied and 45% 
were very satisfied.32 In another study, patients with poor 
local tolerance of their medications noticed improvement of 
subjective symptoms and clinical signs after changing their 
therapy to preservative-free tafluprost 0.0015%.35 Similar 
analyses are needed to compare safety, tolerability, patient 
compliance, and comfort between tafluprost and the other 
prostaglandin analogs.
Conclusion
Both preserved and preservative-free formulations of 
tafluprost are relatively new regimens for glaucoma 
treatment. The results of existing clinical studies of tafluprost 
use are very promising. Despite several studies concerning its 
efficacy, safety, and tolerability, the positioning of tafluprost 
among the antiglaucoma drugs is not well established yet. 
Further analysis is likely to achieve this in the near future.
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